Study Designs for the Estimation of the Hill Parameter in Sigmoidal Response Models

  • Tobias MielkeEmail author
Conference paper
Part of the Contributions to Statistics book series (CONTRIB.STAT.)


Sigmoidal models are frequently considered for the description of the dose-response relationship in dose-finding studies. Designs for these models depend on unknown parameters, which enter the model in a nonlinear way. A particular problem in frequentistic analysis using the sigmoid EMax model is the estimation of the Hill parameter, which may be problematic to estimate. The estimation problem for the Hill parameter and a model-based design approach to limit this problem will be examined in this paper.


Maximum Likelihood Estimator Asymptotic Normality Fisher Information Matrix EMax Model Piecewise Linear Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author is grateful for very valuable discussions and input on this topic from Bjoern Bornkamp, Rainer Schwabe, Vladimir Dragalin and Valerii Fedorov.


  1. 1.
    Bretz, F., Dette, H., Pinheiro, J.: Practical considerations for optimal designs in clinical dose finding studies. Stat. Med. 29, 731–742 (2010)CrossRefMathSciNetGoogle Scholar
  2. 2.
    Committee for Medicinal Products for Human Use (CHMP): Qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty. European Medicines Agency, EMA/CHMP/SAWP/757052/2013 (2014)Google Scholar
  3. 3.
    Dette, H., Kiss, C., Bevanda, M.: Optimal designs for the Emax, log-linear and exponential models. Biometrika 97, 513–518 (2009)CrossRefzbMATHMathSciNetGoogle Scholar
  4. 4.
    Dragalin, V., Hsuan, F., Padmanabhan, S.K.: Adaptive designs for dose finding studies based on sigmoid EMax model. J. Biopharm. Stat. 17, 1051–1070 (2007)CrossRefMathSciNetGoogle Scholar
  5. 5.
    Fedorov, V.V., Leonov, S.L.: Optimal Design for Nonlinear Response Models. Chapman & Hall/CRC Biostatistics Series. CRC Press/Taylor & Francis Group, Boca Raton (2013)zbMATHGoogle Scholar
  6. 6.
    Goutelle, S., Maurin, M., Rougier, F., Barbaut, X., Bourguignon, L., Ducher, M., Maire, P.: The Hill equation: a review of its capabilities in pharmacological modelling. Fundam. Clin. Pharmacol. 22, 633–648 (2008)CrossRefGoogle Scholar
  7. 7.
    Miller, F., Guilbaud, O., Dette, H.: Optimal designs for estimating the interesting part of a dose-effect curve. J. Biopharm. Stat. 17, 1097–1115 (2007)CrossRefMathSciNetGoogle Scholar
  8. 8.
    Silvapulle, M.: On the existence of maximum likelihood estimators for the binomial response models. J. R. Stat. Soc. 43, 310–313 (1981)zbMATHMathSciNetGoogle Scholar
  9. 9.
    Thomas, N., Sweeney, K., Somayaji, V.: Meta-analysis of clinical dose-response in a large drug development portfolio. Stat. Biopharm. Res. 6, 302–317 (2014)CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.ICON Clinical ResearchCologneGermany

Personalised recommendations